Compare · NVO vs PEPG
NVO vs PEPG
Side-by-side comparison of Novo Nordisk A/S (NVO) and PepGen Inc. (PEPG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PEPG operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 1617.6x PEPG ($133.5M).
- Over the past year, NVO is down 29.3% and PEPG is up 34.3% - PEPG leads by 63.6 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for PEPG).
- NVO has more recent analyst coverage (25 ratings vs 5 for PEPG).
- Company
- Novo Nordisk A/S
- PepGen Inc.
- Price
- $48.78+1.22%
- $1.92-7.91%
- Market cap
- $215.95B
- $133.5M
- 1M return
- +2.89%
- +8.78%
- 1Y return
- -29.29%
- +34.27%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 5
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PEPG
- Kalaris Appoints Laurie Keating to Board of Directors
- SEC Form 4 filed by Director Ra Capital Management, L.P.
- PepGen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Wyman Lisa
- SEC Form 4 filed by Director Resnick Joshua
- SEC Form 4 filed by Director Mayer Howard
- SEC Form 4 filed by Director Finer Mitchell H.
- SEC Form 4 filed by Director Dable Habib J
- SEC Form 4 filed by Director Henson Heidi
- SEC Form 4 filed by Director Keating Laurie